Примечания книги С ума сойти! Путеводитель по психическим расстройствам для жителя большого города. Автор книги Дарья Варламова, Антон Зайниев

1

Подробнее о каждом из лекарств см. в соответствующих разделах.

2

Адералл – лекарство от СДВГ, схожее с риталином.

3

В этой главе мы решили не писать про аутизм в целом (хотя это, безусловно, интересная и заслуживающая внимания тема), а сконцентрироваться на высокофункциональном аутизме и синдроме Аспергера. С точки зрения стороннего наблюдателя, именно эти варианты расстройства ближе всего к «нормальности», их носители более или менее интегрированы в общество и визуально мало чем отличаются от обычных людей – и, соответственно, они с большой вероятностью могут встретиться среди ваших коллег, соседей и друзей. Притом от них ожидают того же, что и от обычных людей, поэтому неожиданные проявления их особенностей могут вызвать серьезное непонимание.

4

Под таким названием перевод книги можно найти в Рунете.

5

Использование должностным лицом своих служебных полномочий для удовлетворения личных амбиций вопреки интересам службы. Термин был впервые использован Ф. М. Достоевским в романе «Бесы».

6

Не все герои упомянутых ниже художественных произведений имели официальные диагнозы, но их поведение, по мнению специалистов и/или больных психическими расстройствами, иллюстрирует особенности людей с тем или иным заболеванием.

1

Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Retrieved from http://www.samhsa.gov/data/

2

Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM – IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun; 62(6): 617–27.

3

Lenzenweger MF, Lane MC, Loranger AW, Kessler RC (2007). DSM – IV personality disorders in the National Comorbidity Survey Replication. Biological Psychiatry, 62(6), 553–564.

4

Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry. 1993 Feb; 50(2): 85–94.

5

Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Retrieved from http://www.samhsa.gov/data/

6

http://ria.ru/society/20141010/1027775155.html

7

Kessler RC, Angermeyer M, Anthony Jc, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007; 6(3): 168–176.

8

http://gutta-honey.livejournal.com/113296.html

9

Marazziti D, Akiskal HS, Rossi A, Cassano GB. Alteration of the platelet serotonin transporter in romantic love. Psychol Med. 1999 May; 29(3): 741–5.

10

Bentall RP. A proposal to classify happiness as a psychiatric disorder. Journal of Medical Ethics. 1992; 18(2): 94–98.

11

https://www.youtube.com/watch?v=G_Qwp2GdB1M

12

Dima D, Roiser JP, Dietrich DE, Bonnemann C, Lanfermann H, Emrich HM, Dillo W. Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling. Neuroimage. 2009 Jul 15; 46(4): 1180–6. doi: 10.1016/j.neuroimage.2009.03.033.Epub 2009 Mar 24.

13

Rosenhan DL. On being sane in insane places. Science. 1973 Jan 19; 179(4070): 250–8.

14

Progler Y. Mental illness and social stigma: notes on "How Mad Are You?" Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2009; 14(5): 331–334.

15

Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord. 2009. Se; 117(1–2): 1–17.

16

Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007 May; 13(3): 105–17.

17

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing, p. 20. ISBN978–0–89042–555–8.

18

Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004 Jul; 5(7): 583–9. Review.

19

Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci. 1997 Summer; 9(3): 315–30. Review.

20

Robert Sapolsky (2005). "Biology and Human Behavior: The Neurological Origins of Individuality, 2nd edition". The Teaching Company, p. 13 & 14 of Guide Book.

21

Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb; 101(2): 131–81. Review.

22

Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun; 63(6): 1223–9.

23

Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology. 1997 Feb; 36(2): 233–9.

24

Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5; 102(23): 2836–41.

25

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr; 26(2): 137–44. Review.

26

Hofmann A. (1983). LSD, my problem child: Reflections on sacred drugs, mysticism, and science. Los Angeles: J. P. Tarcher. P. 21.

27

Andersson A, Wiréhn A-B, Ölvander C, Ekman DS, Bendtsen P. Alcohol use among university students in Sweden measured by an electronic screening instrument. BMC Public Health. 2009;9:229. doi: 10.1186/1471-2458-9-229.

28

Kellett J, Kokkinidis L. Extinction deficit and fear reinstatement after electrical stimulation of the amygdala: implications for kindling-associated fear and anxiety. Neuroscience. 2004; 127(2): 277–87.

29

Ghaemi SN. The rise and fall of the biopsychosocial model. Br J Psychiatry. 2009 Jul; 195(1): 3–4. doi: 10.1192/bjp.bp.109.063859.

30

Haygarth, John. (1800). Of the imagination, as a cause and as a cure of disorders of the body; exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath. By John Haygarth, M.D. … Bath: printed by R. Cruttwell; and sold by Cadell and Davies, London.

31

Beecher HK. The powerful placebo. J Am Med Assoc. 1955; 159(17): 1602–6.

32

Howick J, Friedemann C, Tsakok M, et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS ONE. 2013; 8(5): e62599.

33

Linde K, Fässler M, Meissner K. Placebo interventions, placebo effects and clinical practice. Philos Trans R Soc Lond, B, Biol Sci. 2011; 366(1572): 1905–12.

34

Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008; 65(2): 220–31.

35

Oken BS. Placebo effects: clinical aspects and neurobiology. Brain. 2008; 131(Pt 11): 2812–23.

36

Matre D, Casey KL, Knardahl S. Placebo-induced changes in spinal cord pain processing. J Neurosci. 2006; 26(2): 559–63.

37

Qiu YH, Wu XY, Xu H, Sackett D. Neuroimaging study of placebo analgesia in humans. Neurosci Bull. 2009; 25(5): 277–82.

38

Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009; 1156: 198–210.

39

Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol. 2007; 9(4): 176–85.

40

Misra S. Randomized double blind placebo control studies, the "Gold Standard" in intervention based studies. Indian Journal of Sexually Transmitted Diseases. 2012; 33(2): 131–134.

41

Levine R. A Real Mental Ward Becomes A Movie 'Cuckoo's Nest'. The New York Times. April 13, 1975. http://www.nytimes.com/packages/html/movies/bestpictures/cuckoo-ar1.html. Accessed Feb 25, 2016.

42

Tooth GC, and Newton, MP: Leukotomy in England and Wales 1942–1954. London, Her Majesty's Stationary Office, 1961.

43

Jansson B. Controversial Psychosurgery Resulted in a Nobel Prize. Nobel Media AB2014. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1949/moniz-article.html. Accessed Feb 25, 2016.

44

Soares MS, Paiva WS, Guertzenstein EZ, et al. Psychosurgery for schizophrenia: history and perspectives. Neuropsychiatric Disease and Treatment. 2013; 9: 509–515.

45

http://www.youtube.com/watch?v=yQa_sg4zN88

46

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003; 361(9360): 799–808.

47

Fitzgerald PB. Non-pharmacological biological treatment approaches to difficult-to-treat depression. Med J Aust. 2013; 199(6 Suppl): 48–51.

48

Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. Washington, DC: American Psychiatric Publishing, 2001.

49

MacQueen G, Parkin C, Marriott M, Bégin H, Hasey G. The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder. Journal of Psychiatry & Neuroscience. 2007; 32(4): 241–249.

50

Coentre R, Barrocas D, Chendo I, et al. [Electroconvulsive therapy: myths and evidences]. Acta Med Port. 2009; 22(3): 275–80.

51

Cristancho MA, Alici Y, Augoustides JG, O'reardon JP. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep. 2008; 10(6): 474–80.

52

Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol. 2008; 21(1): 3–11.

53

Golenkov A, Ungvari GS, Gazdag G. Public attitudes towards electroconvulsive therapy in the Chuvash Republic. Int J Soc Psychiatry. 2012; 58(3): 289–94.

54

Martin CD. Ernest Hemingway: a psychological autopsy of a suicide. Psychiatry. 2006; 69(4): 351–61.

55

Swartz C. Electroconvulsive and Neuromodulation Therapies. Cambridge University Press; 2009. P. 185–187.

56

Leopold T. (2016, November 18), Sam Phillips, Elvis and the invention of rock 'n' roll, CNN, Available at: http://edition.cnn.com/2015/11/18/entertainment/sam-phillips-sun-records-guralnick-feat/. Accessed February 24, 2016.

57

Rawsthorn A. Yves Saint Laurent, a biography. Nan A. Talese; 1996.

58

The Atlantic Monthly; January 1996; Bud's Bubble; Volume 277, No. 1; pages 99–102.

59

Gardiner H. & Carey B., Researchers Fail to Reveal Full Drug Pay, The New York Times, Jun 8, 2008.

60

Мартынихин И. О состоянии стационарных психиатрических учреждений РФ, Российское общество психиатров (6 декабря 2013 год, 09:35). http://psychiatr.ru/news/192

61

Reininghaus U, Priebe S, Bentall RP. Testing the Psychopathology of Psychosis: Evidence for a General Psychosis Dimension. Schizophrenia Bulletin. 2013; 39(4): 884–895.

62

Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381(9875): 1371–9.

63

Maj M. «Psychiatric comorbidity»: an artefact of current diagnostic systems?. Br J Psychiatry. 2005;186: 182–4.

64

Reininghaus U, Priebe S, Bentall RP. Testing the Psychopathology of Psychosis: Evidence for a General Psychosis Dimension. Schizophrenia Bulletin. 2013; 39(4): 884–895.

65

Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005; 61(7): 835–54.

66

World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.

67

Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys. Epidemiologia e psichiatria sociale. 2009; 18(1): 23–33.

68

Ciftci, Ayse, Nev Jones, and Patrick W. Corrigan. "Mental Health Stigma In The Muslim Community". Journal of Muslim Mental Health 7.1 (2013): n. pag. Web.

69

Xu JM. Some issues in the diagnosis of depression in China. Can J Psychiatry. 1987; 32(5): 368–70.

70

Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013; 10(11).

71

Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013; 43(5): 897–910.

72

Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys. Epidemiologia e psichiatria sociale. 2009; 18(1): 23–33.

73

www.youtube.com/watch?v=NXB6slJSbL4

74

Saint Martin ML. Running Amok: A Modern Perspective on a Culture-Bound Syndrome. Primary Care Companion to The Journal of Clinical Psychiatry. 1999; 1(3): 66–70.

75

http://theoryandpractice.ru/posts/11759-sosland

76

Ablow K., We are raising a generation of deluded narcissists, Fox News, January 08, 2013.

77

Compton WM, Conway KP, Stinson FS, Grant BF. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991–1992 and 2001–2002. Am J Psychiatry. 2006; 163(12): 2141–7.

78

Andrade L, Caraveo-anduaga JJ, Berglund P, et al. The epidemiology of m. Int J Methods Psychiatr Rajor depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. 2003; 12(1): 3–21.

79

Twenge JM, Gentile B, Dewall CN, Ma D, Lacefield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938–2007: A cross-temporal meta-analysis of the MMPI. Clin Psychol Rev. 2010; 30(2): 145–54.

80

Hollan DW, Wellenkamp JC. Contentment and suffering: Culture and experience in Toraja. Columbia Univ Pr; 1994.

81

Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140(3): 205–214. doi: 10.1016/j.jad.2011.12.036.

82

Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140(3): 205–214. doi: 10.1016/j.jad.2011.12.036.

83

Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. Journal of Affective Disorders. 2012; 140(3): 205–214. doi: 10.1016/j.jad.2011.12.036.

84

Hibbeln JR. Fish consumption and major depression. Lancet. 1998; 351(9110): 1213.

85

Kitayama S, Markus HR, Matsumoto H, Norasakkunkit V. Individual and collective processes in the construction of the self: self-enhancement in the United States and self-criticism in Japan. J Pers Soc Psychol. 1997; 72(6): 1245–67.

86

World Health Organization. Global health estimates 2014 summary tables: YLD estimates, 2000–2012, Available: http://www.who.int/entity/healthinfo/global_burden_disease/GHE_YLD_Global_2000_2012.xls. Accessed 20 September 2010.

87

Merikangas KR, He J, Burstein M, et al. Lifetime Prevalence of Mental Disorders in US Adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A). Journal of the American Academy of Child and Adolescent Psychiatry. 2010; 49(10): 980–989. doi:10.1016/j.jaac.2010.05.017.

88

Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U. S. Department of Health and Human Services; 2014.

89

Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS data brief, no 94. Hyattsville, MD: National Center for Health Statistics. 2012.

90

Prevalence of mood disorders in the rural population of Udmurtia. Pakriev, Acta Psychiatr Scand. 1998 Mar; 97(3): 169–74.

91

Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995; 4: 99–105.

92

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994.

93

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.

94

Tsuang MT, Taylor L, Faraone SV. An overview of the genetics of psychotic mood disorders. J Psychiatr Res. 2004; 38: 3–15.

95

Nutt DJ (2008). "Relationship of neurotransmitters to the symptoms of major depressive disorder". Journal of Clinical Psychiatry. 69 Suppl E1: 4–7.

96

Merzenich MM, Nelson RJ, Stryker MP, Cynader MS, Schoppmann A, Zook JM. Somatosensory cortical map changes following digit amputation in adult monkeys. J Comp Neurol. 1984; 224(4): 591–605.

97

Davidson RJ, McEwen BS. Social influences on neuroplasticity: Stress and interventions to promote well-being. Nature neuroscience. 2012; 15(5): 689–695. doi: 10.1038/nn. 3093.

98

Castrén E, Rantamäki T. Neurotrophins in depression and antidepressant effects. Novartis Found Symp. 2008; 289: 43–52.

99

Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010; 70(5): 289–97.

100

Goldman-Rakic PS (October 1996). The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 351(1346): 1445–53.

101

X.T. Wang and Robert D. Dvorak. Sweet Future: Fluctuating Blood Glucose Levels Affect Future Discounting. Psychological Science, 21, 183–188.

102

Maes M. "Functional" or "psychosomatic" symptoms, e. g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett. 2009; 30(5): 564–73.

103

Ryan KA, Dawson EL, Kassel MT, et al. Shared dimensions of performance and activation dysfunction in cognitive control in females with mood disorders. Brain. 2015; 138(Pt 5): 1424–34.

104

Mackin P, Young AH, The Role of Cortisol and Depression: Exploring New Opportunities for Treatments, Psychiatric Times, 2004; 21: 92–5.

105

Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med. 2013; 43(3): 449–69.

106

Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(22): 12320–12322.

107

Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. Hay PJ, ed. PLoS Medicine. 2013; 10(11): e1001547.

108

Соломон Э. Демон полуденный: Анатомия депрессии. – М.: Добрая книга, 2004.

109

Chronic Health Problems among U. S. Adults, by Poverty Status, 2011, Gallup Healthways Well-Being Index.

110

Jonassen R, Chelnokova O, Harmer C, Leknes S, Landrø NI. A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology (Berl). 2015; 232(5): 953–8.

111

Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest. 1952; 21(4): 385–438.

112

Burn JH. The Antihistamine Compounds. British Medical Journal. 1958; 2(5100): 845–846.

113

Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991; 47(1): 4–8.

114

Fagius J, Osterman PO, Sidén A, Wiholm BE. Guillain-Barré syndrome following zimeldine treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 1985; 48(1): 65–69.

115

Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998; 59 Suppl 15: 42–8.

116

Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006; 163(1): 41–7.

117

Dunlop BW, Davis PG. Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review. Primary Care Companion to The Journal of Clinical Psychiatry. 2008; 10(3): 222–228.

118

Постановление Правительства Российской Федерации от 4 февраля 2013 г. № 78 г. Москвы «О внесении изменений в некоторые акты Правительства Российской Федерации».

119

Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry. 1999; 33(3): 323–7.

120

Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, Severity, and Comorbidity of Twelve-month DSM – IV Disorders in the National Comorbidity Survey Replication (NCS-R). Archives of general psychiatry. 2005; 62(6): 617–627. doi: 10.1001/archpsyc.62.6.617.

121

Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther. 2010; 35(2): 177–88.

122

Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother. 2001; 35(12): 1608–13.

123

Pagnin D, De queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004; 20(1): 13–20.

124

Beltman MW, Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Br J Psychiatry. 2010; 197(1): 11–9.

125

Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008; 69(4): 621–32.

126

U. S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health. (2015). Mental Health Information: Depression. Retrieved from http://www.nimh.nih.gov/health/topics/depression/index.shtml.

127

Manber R, Kraemer HC, Arnow BA, et al. Faster Remission of Chronic Depression With Combined Psychotherapy and Medication Than With Each Therapy Alone. Journal of consulting and clinical psychology. 2008; 76(3): 459–467. doi: 10.1037/0022-006X.76.3.459.

128

Lemmens LH, Arntz A, Peeters F, Hollon SD, Roefs A, Huibers MJ. Clinical effectiveness of cognitive therapy v. interpersonal psychotherapy for depression: results of a randomized controlled trial. Psychol Med. 2015; 45(10): 2095–110.

129

Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2. New York: Oxford University Press; 2007.

130

Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73(1–2): 123–31.

131

Roccatagliata G. A History of Ancient Psychiatry. Praeger Pub Text; 1986. (pp. 230–231).

132

Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry. 2010; 67(4): 339–47.

133

Jamison KR. An Unquiet Mind, A Memoir of Moods and Madness. Vintage; 2009, p. 36.

134

Jamison KR. Suicide and Bipolar Disorder. J Clin Psychiatry 2000; 61 (Suppl 9): 47–51.

135

Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry. 2010; 67(4): 339–47.

136

Kerner B. Genetics of bipolar disorder. The Application of Clinical Genetics. 2014; 7: 33–42. doi: 10.2147/TACG.S39297.

137

Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381(9875): 1371–9.

138

Stein DJ, Kupfer DJ, Schatzberg AF. The American Psychiatric Publishing Textbook of Mood Disorders. American Psychiatric Pub; 2007: 159–75.

139

Siegel D. Mindsight, Transform Your Brain with the New Science of Kindness. Oneworld Publications; 2010: 80–101.

140

J. R. Whitwell, Historical Notes on Psychiatry. London: Lewis, 1936.

141

Andreasen NC. The relationship between creativity and mood disorders. Dialogues in Clinical Neuroscience. 2008; 10(2): 251–255.

142

Jamison KR. Mood disorders and patterns of creativity in British writers and artists. Psychiatry. 1989; 52(2): 125–34.

143

Ludwig AM. Creative achievement and psychopathology: comparison among professions. Am J Psychother. 1992; 46(3): 330–56.

144

Santosa CM, Strong CM, Nowakowska C, Wang PW, Rennicke CM, Ketter TA. Enhanced creativity in bipolar disorder patients: a controlled study. J Affect Disord. 2007; 100(1–3): 31–9.

145

Kyaga S, Lichtenstein P, Boman M, Hultman C, Långström N, Landén M. Creativity and mental disorder: family study of 300,000 people with severe mental disorder. Br J Psychiatry. 2011;199(5): 373–9.

146

Frederick K. Googwin, Kay Redfield Jamison. Manic-depressive ilness. Bipolar disorders and reccurent depression. Oxford University Press 2007.

147

Figueroa c G. [Virginia Woolf as an example of a mental disorder and artistic creativity]. Rev Med Chil. 2005; 133(11): 1381–8.

148

Ta-Wei Guu, Kuan-Pin Su. Musical creativity and mood bipolarity in Robert Schumann: A tribute on the 200th anniversary of the composer's birth. Psychiatry and Clinical Neurosciences 2011; 65: 112–114.

149

Stephen G. Michaud, Hugh Aynesworth. The Only Living Witness: The True Story of Serial Sex Killer Ted Bundy.

150

M. Fink, Delirious mania. Bipolar Disorders, vol. 1, no. 1, pp. 54–60, 1999.

151

Fazel S, Lichtenstein P, Grann M, Goodwin GM, Långström N. Bipolar disorder and violent crime: new evidence from population-based longitudinal studies and systematic review. Arch Gen Psychiatry. 2010;67(9): 931–8.

152

https://www.psychologytoday.com/blog/inside-the-criminal-mind/201105/bipolar-illness-or-the-ups-and-downs-the-antisocial-persons

153

Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?. J Affect Disord. 1999; 52(1–3): 135–44.

154

Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. The American journal of psychiatry. 2013; 170(11): 1249–1262. doi: 10.1176/appi.ajp.2013.13020185.

155

Tohen M, Zarate CA, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003; 160(12): 2099–107.

156

Simhandl C, König B, Amann BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry. 2014; 75(3): 254–62.

157

Baethge C, Baldessarini RJ, Mathiske-schmidt K, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry. 2005; 66(2): 174–82.

158

Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders. 2014; 2: 15. doi: 10.1186/s40345-014-0015-8.

159

Van der loos ML, Kölling P, Knoppert-van der klein EA, Nolen WA. [Lamotrigine in the treatment of bipolar disorder, a review]. Tijdschr Psychiatr. 2007; 49(2): 95–103.

160

Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009; 61(2): 185–209.

161

Macritchie K, Geddes JR, Scott J, Haslam D, De lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev. 2003; (1): CD004052.

162

Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1): 4–9.

163

Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar Disorders. 2014;2:15. doi: 10.1186/s40345-014-0015-8.

164

Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194 (1): 4–9.

165

Macritchie K, Geddes JR, Scott J, Haslam D, De lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev. 2003; (1): CD004052.

166

Ushkalova AV, Kostiukova EG, Mosolov SN. [A comparative study of different types of pharmacotherapy in treatment of depressive phase of bipolar II disorder]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(1 Vypusk 2 Depressiia): 23–30.

167

Zaretsky AE, Rizvi S, Parikh SV. How well do psychosocial interventions work in bipolar disorder?. Can J Psychiatry. 2007;5 2(1): 14–21.

168

Frank E, Swartz HA, Mallinger AG, Thase ME, Weaver EV, Kupfer DJ. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol. 1999;108(4): 579–87.

169

Miklowitz DJ. The Bipolar Disorder Survival Guide, Second Edition, What You and Your Family Need to Know. Guilford Press; 2011.

170

Braga RJ, Burdick KE, Derosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res. 2012; 200(2–3):242–5.

171

Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues in Clinical Neuroscience. 2002; 4(3): 231–249.

172

Ohman A, Lundqvist D, Esteves F. The face in the crowd revisited: a threat advantage with schematic stimuli. J Pers Soc Psychol. 2001; 80 (3): 381–96.

173

Pittman CM, Karle EM. Rewire Your Anxious Brain, How to Use the Neuroscience of Fear to End Anxiety, Panic, and Worry. New Harbinger Publications Incorporated; 2014:16–24.

174

Гоулман Д. Эмоциональный интеллект. – М.: ACT, 2009.

175

Amunts K, Kedo O, Kindler M, et al. Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol. 2005; 210(5–6): 343–52.

176

Ledoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol. 2003; 23(4–5): 727–38.

177

Tillich P, Gomes PJ. The Courage to be. New Haven [Conn.]: Yale University Press, 2000.

178

World Health Organization. Global health estimates 2014 summary tables: YLD estimates, 2000–2012, Available: http://www.who.int/entity/healthinfo/global_burden_disease/GHE_YLD_Global_2000_2012.xls. Accessed 8 March 2010.

179

Dupont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996; 2(4): 167–72.

180

Lamers F, Van oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011; 72(3): 341–8.

181

Kessler RC, Berglund PA, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM – IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry.2005 Jun; 62(6): 593–602.

182

King, Helen (1993). "Once upon a text: Hysteria from Hippocrates". In Gilman, Sander; King; Porter, Helen; Rousseau, G.S.; Showalter, Elaine. Hysteria beyond Freud. University of California Press.

183

May R. The Meaning of Anxiety. W. W. Norton; 2015: 40–67.

184

Ibid.

185

Kyaga S, Landén M, Boman M, Hultman CM, Långström N, Lichtenstein P. Mental illness, suicide and creativity: 40-year prospective total population study. J Psychiatr Res. 2013 47(1): 83–90.

186

Silvia, P. J., & Kimbrel, N. A. (in press). A dimensional analysis of creativity and mental illness: Do anxiety and depression symptoms predict creative cognition, creative accomplishments, and creative self-concepts? Psychology of Aesthetics, Creativity, and the Arts.

187

Dommermuth-Costa C. Nikola Tesla, A Spark of Genius. Twenty-First Century Books; 1994: 19–21.

188

Jerry Bergman, Ph.D. 2004. Was Charles Darwin Psychotic? A Study of His Mental Health. Acts & Facts. 33 (1).

189

Panter B, Virshup B. Psychological Studies of Art and Artists. 1996.

190

Фрейд З. Введение в психоанализ. Лекции. – СПб.: Азбука, 2014..

191

Izard CE. The Psychology of Emotions. Springer; 2004. 308–12.

192

Klein DF. Historical aspects of anxiety. Dialogues in Clinical Neuroscience. 2002; 4(3): 295–304.

193

Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005; 81(2): 341–54.

194

Grinde B. An approach to the prevention of anxiety-related disorders based on evolutionary medicine. Prev Med. 2005; 40(6): 904–9.

195

Price JS. Evolutionary aspects of anxiety disorders. Dialogues in Clinical Neuroscience. 2003; 5(3): 223–236.

196

Watson JB, Rayner R. Conditioned emotional reactions. 1920. Am Psychol. 2000; 55(3): 313–7.

197

Beck, H. P., Levinson, S., & Irons, G. (2009). "Finding Little Albert: A journey to John B. Watson's infant laboratory". American Psychologist, 64, 7.

198

Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009; 66(12): 1361–72.

199

Adolphs R, Tranel D, Hamann S, et al. Recognition of facial emotion in nine individuals with bilateral amygdala damage. Neuropsychologia. 1999; 37(10): 1111–7.

200

Haygarth, John. (1800). Of the imagination, as a cause and as a cure of disorders of the body; exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath. By John Haygarth, M.D. … Bath: printed by R. Cruttwell; and sold by Cadell and Davies, London.

201

Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry. 2003; 64 Suppl 3: 21–7.

202

Stein MB, Goin MK, Pollack MH, Roy-Byrne P, Sareen J, Simon NM, et al. Practice guideline for the treatment of patients with panic disorder. Arlington, VA: American Psychiatric Association, 2009.

203

Association, American Psychiatric (2013). Diagnostic and statistical manual of mental disorders: DSM-5. (5th ed.). Washington, D.C.: American Psychiatric Association. p. 222.

204

Heinze HJ, Mangun GR, Burchert W, et al. Combined spatial and temporal imaging of brain activity during visual selective attention in humans. Nature. 1994; 372(6506): 543–6.

205

Bateson M, Brilot B, Nettle D. Anxiety: an evolutionary approach. Can J Psychiatry. 2011; 56(12): 707–15.

206

Lundström JN, Olsson MJ. Functional Neuronal Processing of Human Body Odors. Vitamins and hormones. 2010; 83: 1–23. doi: 10.1016/S0083–6729(10)83001–8.

207

Morgan E. The Scars of Evolution. Oxford University Press on Demand; 100–1, 1994.

208

Depersonalization: A New Look at a Neglected Syndrome By Mauricio Sierra, p. 154.

209

Favazza, A. (2012). Nonsuicidal self-injury: How categorization guides treatment. Current Psychiatry, 11, 21–26.

210

Prodigal Genius: The Life of Nikola Tesla By John J. O'Neil, 293.

211

Wilson, Bee, The Telegraph, "Alfred Hitchcock's complicated relationship with food," (http://www.telegraph.co.uk/journalists/bee-wilson/9818987/Alfred-Hitchcocks-complicated-relationship-with-food.html), March 8, 2016.

212

Salvador Dal', Or the Art of Spitting on Your Mother's Portrait By Carlos Rojas, p. 46.

213

Rapee RM. Family factors in the development and management of anxiety disorders. Clin Child Fam Psychol Rev. 2012; 15 (1): 69–80.

214

Kendler K, Karkowski L, Prescott C (1999). "Fears and phobias: reliability and heritability". Psychological Medicine 29 (3): 539–53.

215

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM – IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602.

216

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM – IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602.

217

Брайсон Б. Краткая история почти всего на свете. – М.: АСТ, 2016.

218

Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006; 63(4): 415.

219

Yardley L, Britton J, Lear S, Bird J, Luxon LM. Relationship between balance system function and agoraphobic avoidance. Behav Res Ther. 1995; 33(4): 435–9.

220

Jacob RG, Furman JM, Durrant JD, Turner SM. Panic, agoraphobia, and vestibular dysfunction. Am J Psychiatry. 1996; 153(4): 503–12.

221

http://neilhilborn.tumblr.com/post/56192842620/buttonpoetry-neil-hilborn-ocd-rustbelt

222

Association, American Psychiatric (2013). Diagnostic and statistical manual of mental disorders: DSM-5. (5th ed.). Washington, D.C.: American Psychiatric Association. p. 237.

223

Fitzgerald KD, Welsh RC, Stern ER, et al. Developmental alterations of frontal-striatal-thalamic connectivity in obsessive compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2011; 50(9): 938–948.e3. doi: 10.1016/j.jaac.2011.06.011.

224

Ahmari SE, Spellman T, Douglass NL, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013; 340(6137): 1234–9.

225

Miller JA, Research Update BioScience. Vol. 42, No. 4 (Apr., 1992), pp. 257–261.

226

Einstein DA, Menzies RG. Role of magical thinking in obsessive-compulsive symptoms in an undergraduate sample. Depress Anxiety. 2004; 19(3): 174–9.

227

Shin LM, Shin PS, Heckers S, et al. Hippocampal function in posttraumatic stress disorder. Hippocampus. 2004; 14(3): 292–300.

228

Skelton K, Ressler KJ, Norrholm SD, Jovanovic T, Bradley-davino B. PTSD and gene variants: new pathways and new thinking. Neuropharmacology. 2012; 62(2): 628–37.

229

Van der kolk B. Posttraumatic stress disorder and the nature of trauma. Dialogues Clin Neurosci. 2000; 2(1): 7–22.

230

Hirschfeld RMA. The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. Primary Care Companion to The Journal of Clinical Psychiatry. 2001; 3(6): 244–254.

231

Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry. 1992; 49(9): 716–22.

232

Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003; 8(8 Suppl 1): 53–61.

233

Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000; 59(2): 119–26.

234

Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013; 12(2): 137–48.

235

Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues in Clinical Neuroscience. 2011; 13(4): 413–421.

236

Clapp P, Bhave SV, Hoffman PL. How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective. Alcohol Res Health. 2008; 31(4): 310–39.

237

Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of Psychiatry and Neuroscience. 2003; 28(4): 263–274.

238

Smith JP, Randall CL. Anxiety and alcohol use disorders: comorbidity and treatment considerations. Alcohol Res. 2012; 34(4): 414–31.

239

McGovern TF, White WL. Alcohol Problems in the United States, Twenty Years of Treatment Perspective. Haworth Press; 2002. 5–40.

240

Somnath Banerjee (2012). ADHD in Children and Adolescents: A Good Practice Guidance, Current Directions in ADHD and Its Treatment, Dr. Jill M. Norvilitis (Ed.).

241

Ratey NA. The Disorganized Mind, Coaching Your ADHD Brain to Take Control of Your Time, Tasks, and Talents. St. Martin's Press, 2008.

242

Hodgkins P, Arnold LE, Shaw M, et al. A Systematic Review of Global Publication Trends Regarding Long-Term Outcomes of ADHD. Frontiers in Psychiatry. 2011; 2: 84.

243

Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Attention Deficit and Hyperactivity Disorders. 2010; 2(4): 241–255.

244

Ratey NA. The Disorganized Mind, Coaching Your ADHD Brain to Take Control of Your Time, Tasks, and Talents. St. Martin's Press, 2008.

245

Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Attention Deficit and Hyperactivity Disorders. 2010; 2(4): 241–255.

246

Strohl MP. Bradley's Benzedrine Studies on Children with Behavioral Disorders. The Yale Journal of Biology and Medicine. 2011; 84(1): 27–33.

247

Myers RL. The 100 Most Important Chemical Compounds, A Reference Guide. ABC–CLIO; 2007: 178–80.

248

Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial ties between DSM – IV panel members and the pharmaceutical industry. Psychother Psychosom. 2006;75(3): 154–60.

249

Americans With Disabilities Act of 1990, Pub. L. No. 101–336, 104 Stat. 328 (1990).

250

Kessler, R.C., Adler, L., Ames, M., Demler, O., Faraone, S., Hiripi, E., Howes, M.J., Jin, R., Secnik, K., Spencer, T., Ustun, T.B., Walters, E.E. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS). Psychological Medicine, 35(2), 245–25.

251

Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010; 10: 67.

252

Arria AM, Wish ED. Nonmedical Use of Prescription Stimulants Among Students. Pediatric annals. 2006; 35(8): 565–571.

253

Garnier-Dykstra LM, Caldeira KM, Vincent KB, O'Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: Four-year trends in exposure opportunity, use, motives, and sources. Journal of American College Health: J of ACH. 2012; 60(3): 226–234.

254

Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000; 10(4): 311–20.

255

Faraone SV. Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T. 2009; 34(12): 678–94.

256

Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature. Prim Care Companion CNS Disord. 2014; 16(3).

257

Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009; 126(1): 51–90.

258

Mccarthy H, Skokauskas N, Mulligan A, et al. Attention network hypoconnectivity with default and affective network hyperconnectivity in adults diagnosed with attention-deficit/hyperactivity disorder in childhood. JAMA Psychiatry. 2013; 70(12): 1329–37.

259

Safer DJ, Krager JM. Treatment of Attention-Deficit Hyperactivity Disorder-Reply. JAMA. 1993; 269(18): 2369.

260

Maraini D, Dacia Maraini Intervista Giorgio Antonucci. La Stampa, 26.7., 29 e 30.12.'78.

261

Moffitt T, Melchior M. Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter? The American Journal of Psychiatry. 2007; 146(6): 856–858. doi: 10.1176/appi.ajp.164.6.856.

262

Shaw, P., Malek, M., Watson, B., Greenstein, D., de Rossi, P., & Sharp, W. (2013). Trajectories of Cerebral Cortical Development in Childhood and Adolescence and Adult Attention-Deficit/Hyperactivity Disorder, Biological Psychiatry, 74, 599–606.

263

Sripada CS, Kessler D, Angstadt M. Lag in maturation of the brain's intrinsic functional architecture in attention-deficit/hyperactivity disorder. Proc Natl Acad Sci USA. 2014; 111(39): 14259–64.

264

Volkow ND, Wang G-J, Newcorn JH, et al. Motivation Deficit in ADHD is Associated with Dysfunction of the Dopamine Reward Pathway. Molecular psychiatry. 2011;16(11): 1147–1154. doi: 10.1038/mp.2010.97.

265

Голдберг Э. Управляющий мозг: Лобные доли, лидерство и цивилизация. – М.: Смысл, 2003.

266

Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.

267

Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry. 2002; 41 (4): 378–85.

268

Ibid.

269

Hartmann T. Attention Deficit Disorder, A Different Perception. Underwood Books; 1997.

270

Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.

271

Gilman L, Career Advice from the Corner Office: Famous People with ADHD, ADDitude, 2005 Dec-Jan.

272

Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.

273

World Health Organization (2012). Pharmacological and nonpharmacological interventions for children with attention-deficit hyperactivity disorder (ADHD). Geneva: WHO.

274

Philipsen A, Richter H, Peters J, et al. Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study. J Nerv Ment Dis. 2007; 195(12): 1013–9.

275

Weiss M, Murray C, Wasdell M, Greenfield B, Giles L, Hechtman L. A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. BMC Psychiatry. 2012; 12:30. doi: 10.1186/1471-244X-12–30.

276

Morton WA, Stockton GG. Methylphenidate Abuse and Psychiatric Side Effects. Primary Care Companion to The Journal of Clinical Psychiatry. 2000; 2(5): 159–164.

277

Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the Efficacy of Medications for ADHD Using Meta-analysis. Medscape General Medicine. 2006; 8(4): 4.

278

Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005; 43(7): 831–42.

279

Зиновьева А. Космический пришелец по имени Иван // Московский комсомолец. – 2013. – 5 июля (№ 26272).

280

Schechter MD, Timmons GD. Objectively measured hyperactivity – II. Caffeine and amphetamine effects. J Clin Pharmacol. 1985; 25(4): 276–80.

281

Arnold LE, Christopher J, Huestis R, Smeltzer DJ. Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis. Arch Gen Psychiatry. 1978; 35(4): 463–73.

282

Archer D. The ADHD Advantage, What You Thought Was a Diagnosis May Be Your Greatest Strength. Hudson Street Press; 2015.

283

Wing L. The history of ideas on autism: Legends, myths and reality. Autism. 1997; 1: 13–23.

284

Miles, M. "Martin Luther and Childhood Disability in 16th Century Germany: What Did He Write? What Did He Say?" Journal of Religion, Disability, and Health 5, no. 4: 5–36.

285

Houston R, Frith U. Autism in History, The Case of Hugh Blair of Borgue. Wiley-Blackwell; 2000.

286

Rapaport, David, (1951). Organization and pathology of thought: Selected sources., (pp. 399–437). New York, NY, US: Columbia University Press, xviii, 786 pp.

287

Baron-Cohen S, Klin A. What's so special about Asperger Syndrome?. Brain Cogn. 2006; 61(1): 1–4.

288

Wing L. Asperger's syndrome: a clinical account. Psychol Med. 1981; 11(1): 115–29.

289

Silberman S. NeuroTribes, The Legacy of Autism and How to Think Smarter About People Who Think Differently. 2016.

290

Feinstein A. A History of Autism, Conversations with the Pioneers. Wiley-Blackwell; 2010.

291

Yu KK, Cheung C, Chua SE, Mcalonan GM. Can Asperger syndrome be distinguished from autism? An anatomic likelihood meta-analysis of MRI studies. J Psychiatry Neurosci. 2011; 36(6): 412–21.

292

Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013; 12(2): 92–98. doi: 10.1002/wps.20050.

293

Peek K., Inspiration for 'Rain Man,' Dies at 58, The New York Times, December 27, 2009, A30.

294

Treffert DA. The savant syndrome and autistic disorder. CNS Spectr. 1999; 4(12): 57–60.

295

Klin A. [Autism and Asperger syndrome: an overview]. Rev Bras Psiquiatr. 2006; 28 Suppl 1: S3–11.

296

Klin A. [Autism and Asperger syndrome: an overview]. Rev Bras Psiquiatr. 2006; 28 Suppl 1: S3–11.

297

Roy M, Dillo W, Emrich HM, Ohlmeier MD. Asperger's syndrome in adulthood. Dtsch Arztebl Int. 2009; 106(5): 59–64.

298

Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. J Child Psychol Psychiatry. 2005; 46(12): 1255–68.

299

Allely CS. Pain Sensitivity and Observer Perception of Pain in Individuals with Autistic Spectrum Disorder. The Scientific World Journal. 2013; 2013: 916178.

300

Green D, Baird G, Barnett AL, Henderson L, Huber J, Henderson SE. The severity and nature of motor impairment in Asperger's syndrome: a comparison with specific developmental disorder of motor function. J Child Psychol Psychiatry. 2002; 43(5): 655–68.

301

Blakemore SJ, Tavassoli T, Calò S, et al. Tactile sensitivity in Asperger syndrome. Brain Cogn. 2006; 61(1): 5–13.

302

Lugnegård T, Hallerbäck MU, Gillberg C. Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Res Dev Disabil. 2011; 32(5): 1910–7.

303

Miles JH, McCathren RB, Stichter J, et al. Autism Spectrum Disorders. 2003 Aug 27 [Updated 2010 Apr 13]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1442/

304

South M, Ozonoff S, Mcmahon WM. Repetitive behavior profiles in Asperger syndrome and high-functioning autism. J Autism Dev Disord. 2005; 35(2): 145–58.

305

Boyd BA, McDonough SG, Bodfish JW. Evidence-Based Behavioral Interventions for Repetitive Behaviors in Autism. Journal of autism and developmental disorders. 2012; 42(6): 1236–1248.

306

Newman SS, Ghaziuddin M. Violent crime in Asperger syndrome: the role of psychiatric comorbidity. J Autism Dev Disord. 2008; 38(10): 1848–52.

307

Mouridsen SE, Rich B, Isager T, Nedergaard NJ. Pervasive developmental disorders and criminal behaviour: a case control study. Int J Offender Ther Comp Criminol. 2008; 52(2): 196–205.

308

Mazefsky CA, Herrington J, Siegel M, et al. The Role of Emotion Regulation in Autism Spectrum Disorder RH: Emotion Regulation in ASD. Journal of the American Academy of Child and Adolescent Psychiatry. 2013; 52(7): 679–688. doi: 10.1016/j.jaac.2013.05.006.

309

Ghaziuddin M, Tsai L, Ghaziuddin N. Brief report: violence in Asperger syndrome, a critique. J Autism Dev Disord. 1991; 21(3): 349–54.

310

Castillo M., Asperger's not likely to make people violent, experts emphasize, CBS News, December 17, 2012.

311

Baez S, Rattazzi A, Gonzalez-gadea ML, et al. Integrating intention and context: assessing social cognition in adults with Asperger syndrome. Front Hum Neurosci. 2012; 6: 302.

312

Zalla T, Sav AM, Stopin A, Ahade S, Leboyer M. Faux pas detection and intentional action in Asperger Syndrome. A replication on a French sample. J Autism Dev Disord. 2009; 39(2): 373–82.

313

Henry O'Connell and Michael Fitzgerald (2003). Did Alan Turing have Asperger's syndrome?. Irish Journal of Psychological Medicine, 20, pp. 28–31.

314

Decety J, Moriguchi Y. The empathic brain and its dysfunction in psychiatric populations: implications for intervention across different clinical conditions. Biopsychosoc Med. 2007; 1: 22.

315

Raftery B., How Dan Harmon Drives Himself Crazy Making Community, Wired, 09.2011.

316

Grove R, Baillie A, Allison C, Baron-Cohen S, Hoekstra RA. The latent structure of cognitive and emotional empathy in individuals with autism, first-degree relatives and typical individuals. Molecular Autism. 2014; 5: 42. doi: 10.1186/2040-2392-5-42.

317

Mazza M, Pino MC, Mariano M, et al. Affective and cognitive empathy in adolescents with autism spectrum disorder. Front Hum Neurosci. 2014; 8: 791.

318

Mcintosh DN, Reichmann-decker A, Winkielman P, Wilbarger JL. When the social mirror breaks: deficits in automatic, but not voluntary, mimicry of emotional facial expressions in autism. Dev Sci. 2006; 9(3): 295–302.

319

Markram H, Rinaldi T, Markram K. The Intense World Syndrome – an Alternative Hypothesis for Autism. Frontiers in Neuroscience. 2007; 1(1): 77–96. doi: 10.3389/neuro.01.1.1.006.2007.

320

Hayashi M, Kato M, Igarashi K, Kashima H. Superior fluid intelligence in children with Asperger's disorder. Brain Cogn. 2008; 66(3): 306–10.

321

Baron-Cohen S, Golan O, Ashwin E. Can emotion recognition be taught to children with autism spectrum conditions? Philosophical Transactions of the Royal Society B: Biological Sciences. 2009; 364(1535): 3567–3574.

322

Segar M. Faire face, guide de survie à l'intention des personnes atteintes du syndrome d'Asperger. 1998.

323

http://www.aspergers.ru/node/94

324

Willingham D., 'Wall Street' Actress Daryl Hannah Is An Autistic Woman, Forbes, 9.29.2013.

325

Shattuck PT, Narendorf SC, Cooper B, Sterzing PR, Wagner M, Taylor JL. Postsecondary education and employment among youth with an autism spectrum disorder. Pediatrics. 2012; 129(6): 1042–9.

326

James I. Singular scientists. Journal of the Royal Society of Medicine. 2003; 96(1): 36–39.

327

Ruthsatz, J., & Urbach, J. B., Child prodigy: A novel cognitive profile places elevated general intelligence, exceptional working memory and attention to detail… Intelligence (2012).

328

Baron-Cohen S, Bolton P, Wheelwright S, Scahill V, Short L, Mead G, Smith A. Does autism occur more often in families of physicists, engineers, and mathematicians? Autism. 1998; 2 (3): 296–301.

329

Clarke T-K. et al. Common polygenic risk for autism spectrum disorder (ASD) is associated with cognitive ability in the general population. Molecular Psychiatry. 2015. March 10.

330

Frith U. Emanuel Miller lecture: confusions and controversies about Asperger syndrome. J Child Psychol Psychiatry. 2004; 45(4): 672–86.

331

Grove R, Roth I, Hoekstra RA. The motivation for special interests in individuals with autism and controls: Development and validation of the special interest motivation scale. Autism Res. 2015.

332

Prior M, Ozonoff S (2007). "Psychological factors in autism". In Volkmar FR. Autism and Pervasive Developmental Disorders (2nd ed.). Cambridge University Press. pp. 69–128.

333

http://youtu.be/i_yJTCDU4uE

334

Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry. 2007; 12(1): 2–22.

335

Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006; 29(7): 349–58.

336

Courchesne E, Mouton PR, Calhoun ME, et al. Neuron Number and Size in Prefrontal Cortex of Children With Autism. JAMA. 2011; 306(18): 2001–2010.

337

Kanold PO. Subplate neurons: crucial regulators of cortical development and plasticity. Front Neuroanat. 2009; 3: 16.

338

Hadjikhani N, Joseph RM, Snyder J, Tager-flusberg H. Anatomical differences in the mirror neuron system and social cognition network in autism. Cereb Cortex. 2006; 16(9): 1276–82.

339

Cheng Y, Yang CY, Lin CP, Lee PL, Decety J. The perception of pain in others suppresses somatosensory oscillations: a magnetoencephalography study. Neuroimage. 2008; 40(4): 1833–40.

340

Lamm C, Batson CD, Decety J. The neural substrate of human empathy: effects of perspective-taking and cognitive appraisal. J Cogn Neurosci. 2007; 19(1): 42–58.

341

Botvinick M, Jha AP, Bylsma LM, Fabian SA, Solomon PE, Prkachin KM. Viewing facial expressions of pain engages cortical areas involved in the direct experience of pain. Neuroimage. 2005; 25(1): 312–9.

342

Jabbi M, Swart M, Keysers C. Empathy for positive and negative emotions in the gustatory cortex. Neuroimage. 2007; 34(4): 1744–53.

343

Hamilton AF. Goals, intentions and mental states: challenges for theories of autism. J Child Psychol Psychiatry. 2009; 50(8): 881–92.

344

Dinstein I, Thomas C, Humphreys K, Minshew N, Behrmann M, Heeger DJ. Normal movement-selectivity in autism. Neuron. 2010; 66(3): 461–469. doi: 10.1016/j.neuron.2010.03.034.

345

Ramachandran VS, Oberman LM. Broken mirrors: a theory of autism. Sci Am. 2006; 295(5): 62–9.

346

Baron-Cohen S, Leslie AM, Frith U. Does the autistic child have a "theory of mind"?. Cognition. 1985; 21(1): 37–46.

347

Ruffman T, Garnham W, Rideout P. Social understanding in autism: eye gaze as a measure of core insights. J Child Psychol Psychiatry. 2001; 42(8): 1083–94.

348

RETRACTED: Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637–41.

349

Fraser M., Anti-MMR doctor is forced out, The Telegraph, 02 Dec 2001.

350

Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. MP, Mol Pathol. 2002; 55(2): 84–90.

351

Goldacre M., The MMR hoax, The Guardian, 30 August 2008.

352

Health and Social Care Information Centre, NHS Immunisation Statistics England 2012–13, 26 September 2013.

353

Deer B., MMR doctor Andrew Wakefield fixed data on autism, The Sunday Times, 8 February 2009.

354

Horton R. The lessons of MMR. Lancet. 2004; 363 (9411): 747–9.

355

Miriam Falco, Vaccine study's author held related patent, medical journal reports, CNN, January 12, 2011.

356

RETRACTED: Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998; 351(9103): 637–41.

357

Flaherty DK. The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Ann Pharmacother. 2011; 45(10): 1302–4.

358

Health and Social Care Information Centre, NHS Immunisation Statistics England 2012–13, 26, September 2013.

359

Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014; 32(29): 3623–9.

360

Seida JK, Ospina MB, Karkhaneh M, Hartling L, Smith V, Clark B. Systematic reviews of psychosocial interventions for autism: an umbrella review. Dev Med Child Neurol. 2009; 51(2): 95–104.

361

Eikeseth S. Outcome of comprehensive psycho-educational interventions for young children with autism. Res Dev Disabil. 2009; 30(1): 158–78.

362

Buitelaar JK. Why have drug treatments been so disappointing?. Novartis Found Symp. 2003; 251: 235–44.

363

Nicholas Lofthouse, Robert Hendren, Elizabeth Hurt, L. Eugene Arnold, and Eric Butter, "A Review of Complementary and Alternative Treatments for Autism Spectrum Disorders," Autism Research and Treatment, vol. 2012, 2012.

364

Tonya N. Davis et al., "Chelation Treatment for Autism Spectrum Disorders: A Systematic Review," Research in Autism Spectrum Disorders 7 (January 2013): 49–55.

365

Tonya N. Davis et al., "Chelation Treatment for Autism Spectrum Disorders: A Systematic Review," Research in Autism Spectrum Disorders 7 (January 2013): 49–55.

366

Myles, B. S., Huggins, A., Rome-Lake, M., Hagiwara, T., Barnhill, G. P., & Griswold, D. E. (2003). Written Language Profile of Children and Youth with Asperger Syndrome: From Research to Practice. Education and Training in Developmental Disabilities, 38(4), 362–369.

367

Blume H., Autistics, freed from face-to-face encounters, are communicating in cyberspace. The New York Times, June 30, 1997.

368

Saner E., 'It is not a disease, it is a way of life', The Guardian, 7 August 2007.

369

https://www.autismspeaks.org/liub

370

General Assembly resolution 62/139, World Autism Awareness Day, A/RES/62/139 (21 January 2008), available from undocs.org/A/RES/62/139.

371

Morel BA. Traité des maladies mentales. [Treatise on mental diseases]. Paris, France: Masson; 1860.

372

Berrios GE. Phthisical insanity by T. S. Clouston. Hist Psychiatry. 2005; 16(Pt 4 (no 64)): 473–9.

373

Hecker E. Die Hebephrenie: ein Beitrag zur klinischen Psychiatrie. [Hebephrenia: a contribution to clinical psychiatry] Archiv für pathologische Anatomie und für klinische Medizin. 1871.

374

Kahlbaum KL. Die Gruppierung der psychischen Krankheiten und die Einteilung der Seelenstörungen. [The Grouping of Psychiatric Diseases and the Classification of Mental Disturbances]. Danzig, Germany: Kafemann; 1863.

375

Kraepelin E. Psychiatrie. 6 Auflage. Leipzig, Austria: Barth 1899. English translation by Metoui H, Ayed S: Psychiatry, A Textbook for Students and Physicians.

376

Waters FA, Badcock JC, Dragovic´ M, Jablensky A. Neuropsychological functioning in schizophrenia patients with first-rank (passivity) symptoms. Psychopathology. 2009; 42(1): 47–58.

377

Wilkinson G. Political dissent and "sluggish" schizophrenia in the Soviet Union. British Medical Journal (Clinical research ed). 1986; 293(6548): 641–642.

378

Bonnie RJ. Political abuse of psychiatry in the Soviet Union and in China: complexities and controversies. J Am Acad Psychiatry Law. 2002; 30(1): 136–44.

379

World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.

380

Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987; 151: 145–51.

381

Johnstone EC, Frith CD. Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients. Psychol Med. 1996; 26(4): 669–79.

382

Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry. 1995; 52(5): 352–60.

383

World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.

384

Lindström, E et al., The ICD-10 and DSM – IV diagnostic criteria and the prevalence of schizophrenia, European Psychiatry, (1997). Volume 12, Issue 5, 217–223.

385

Upthegrove R, Birchwood M, Ross K, Brunett K, Mccollum R, Jones L. The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand. 2010; 122(3): 211–8.

386

Sham PC, Maclean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand. 1994; 89(2): 135–41.

387

Brugha T, Singleton N, Meltzer H, et al. Psychosis in the community and in prisons: a report from the British National Survey of psychiatric morbidity. Am J Psychiatry. 2005; 162(4): 774–80.

388

Ostling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry. 2002; 59(1): 53–9.

389

Лаувенг А. Завтра я всегда бывала львом. – М.: Бахрах-М, 2012.

390

Trémeau F, Antonius D, Cacioppo JT, et al. In support of Bleuler: objective evidence for increased affective ambivalence in schizophrenia based upon evocative testing. Schizophr Res. 2009; 107(2–3): 223–31.

391

De Clerambault, Psychoses a base d'automatisme (1925), La Psychiatrie, 1994: 511.

392

Kiran C, Chaudhury S. Understanding delusions. Industrial Psychiatry Journal. 2009; 18(1): 3–18.

393

О'Брайен Б. Необыкновенное путешествие в безумие и обратно: Операторы и вещи. – М.: Класс, 1996.

394

Byrne P. Managing the acute psychotic episode. BMJ: British Medical Journal. 2007; 334(7595): 686–692.

395

Van rensburg AB, Olorunju S. Diagnosis and treatment of schizophrenia in a general hospital based acute psychiatric ward. Afr J Psychiatry (Johannesbg). 2010; 13(3): 204–10.

396

Surviving Schizophrenia: A Manual for Families, Patients, and Providers (5th Edition) by E. Fuller Torrey (Author), Publisher: Quill; 5th edition (April 1, 2006).

397

Mitchison A., Kim Noble: The woman with 100 personalities, The Guardian, 30 September 2011.

398

Nathan PE, Gorman JM. A Guide to Treatments that Work. Oxford University Press, USA; 2007: 463–5.

399

Beidel DC, Frueh BC, Hersen M. Adult Psychopathology and Diagnosis. John Wiley & Sons; 2014.

400

Korol S. Familial and social support as protective factors against the development of dissociative identity disorder. J Trauma Dissociation. 2008; 9(2): 249–67.

401

Gillig PM. Dissociative identity disorder: a controversial diagnosis. Psychiatry (Edgmont). 2009; 6(3): 24–9.

402

Galvin JE, Sadowsky CH. Practical guidelines for the recognition and diagnosis of dementia. J Am Board Fam Med. 2012; 25(3): 367–82.

403

Burns A, Iliffe S. Dementia. BMJ. 2009; 338: b75.

404

Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007; 6(11): 994–1003.

405

O'donovan MC, Williams NM, Owen MJ. Recent advances in the genetics of schizophrenia. Hum Mol Genet. 2003; 12 Spec № 2: R125–33.

406

Torrey EF. Surviving Schizophrenia, 6th Edition, A Family Manual. Harper Perennial; 2013: 135.

407

Van os J, Kapur S. Schizophrenia. Lancet. 2009; 374(9690): 635–45.

408

Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999; 56(2): 162–8.

409

Kendler KS, Mcguire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry. 1993; 50(7): 527–40.

410

O'Donovan MC, Williams NM, Owen MJ. Recent advances in the genetics of schizophrenia. Hum Mol Genet. 2003; 12 Spec № 2: R125–33.

411

Torrey EF, Yolken RH. Psychiatric Genocide: Nazi Attempts to Eradicate Schizophrenia. Schizophrenia Bulletin. 2010; 36(1): 26–32.

412

Crow TJ. Schizophrenia as the price that homo sapiens pays for language: a resolution of the central paradox in the origin of the species. Brain Res Brain Res Rev. 2000; 31(2–3): 118–29.

413

Burns JK. An evolutionary theory of schizophrenia: cortical connectivity, metarepresentation, and the social brain. Behav Brain Sci. 2004; 27(6): 831–55.

414

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull. 2009; 35(3): 549–62.

415

Carlsson A., Carlsson ML. Dopaminergic stabilisers. Adv Schizophrenia and Clin Psychiatry. 2005; 1: 118–128.

416

Da silva alves F, Figee M, Van amelsvoort T, Veltman D, De haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull. 2008; 41(1): 121–32.

417

Pogarell O, Koch W, Karch S, et al. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry, 2012; 45 Suppl 1: S36–41.

418

Mechri A, Saoud M, Khiari G, D'amato T, Dalery J, Gaha L. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. Encephale. 2001; 27(1): 53–9.

419

Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr Res. 2005; 73(2–3): 147–52.

420

Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012; 38(5): 920–6.

421

Richard A, Churan J, Whitford V, O'driscoll GA, Titone D, Pack CC. Perisaccadic perception of visual space in people with schizophrenia. J Neurosci. 2014; 34(14):4760–5.

422

Bateson, G., Jackson, D. D., Haley, J. & Weakland, J. (1956), Towards a Theory of Schizophrenia. in Behavioral Science, Vol 1, 251–264.

423

Large M, Smith G, Nielssen O. The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis. Schizophr Res. 2009; 112(1–3):123–9.

424

Phelan, J. C., Link, B. G., Stueve, A., & Pescosolido, B. A. (2000). Public Conceptions of Mental Illness in 1950 and 1996: What Is Mental Illness and Is It to be Feared? Journal of Health and Social Behavior, 41(2), 188–207.

425

Pronin, E., Perception and misperception of bias in human judgment, (2007) Trends in Cognitive Sciences, Volume 11, Issue 1, 37–43.

426

Walsh E, Fahy T. Violence in society: Contribution of mental illness is low. BMJ: British Medical Journal. 2002; 325(7363): 507–508.

427

Burton N. The Meaning of Madness. Oxford: Acheron Press, 2009; 2008.

428

Kaufman SB, How Is Creativity Differentially Related to Schizophrenia and Autism? Scientific American, June 10, 2015

429

Marquis DM. In Search of Buddy Bolden, First Man of Jazz. LSU Press; 2005.

430

Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry. 2005; 50(14): 892–900.

431

Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506–17.

432

Saks ER., Diary of a High-Functioning Person with Schizophrenia, Scientific American, December 29, 2009.

433

Wiersma D, Wanderling J, Dragomirecka E, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med. 2000; 30 (5): 1155–67.

434

Ruhrmann S, Schultze-lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010; 67(3): 241–51.

435

Doroshow DB. Performing a cure for schizophrenia: insulin coma therapy on the wards. J Hist Med Allied Sci. 2007;62 (2):213–43.

436

Raz M. The painless brain: lobotomy, psychiatry, and the treatment of chronic pain and terminal illness. Perspect Biol Med. 2009; 52(4): 555–65.

437

Epstein NN. Artificial Fever as a Therapeutic Procedure. Cal West Med. 1936; 44(5): 357–8.

438

"The Nobel Prize in Physiology or Medicine 1927". Nobelprize.org. Nobel Media AB2014. Web. 14 Mar 2016. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1927/

439

Hamon, Paraire, Velluz. [Effect of R. P. 4560 on maniacal agitation]. Ann Med Psychol (Paris). 1952; 110: 331–5.

440

Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment. 2007; 3(4): 495–500.

441

Ban TA. Pharmacotherapy of mental illness – a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(4): 709–27.

442

Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues in Clinical Neuroscience. 2006; 8(1):137–142.

443

Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010; 81(5): 617–22.

444

Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18(1): 39–60.

445

Brisch R, Saniotis A, Wolf R, et al. The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue. Frontiers in Psychiatry. 2014; 5:47. doi: 10.3389/fpsyt.2014.00047.

446

Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry. 2001; 179: 503–8.

447

Хаэр Р. Лишенные совести: Пугающий мир психопатов. – М.: Вильямс, 2014.

448

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.

449

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing.

450

Ющенко А. И. Основы учений о преступнике, душевнобольном и психологии нормального человека. Введение в курс судебной психопатологии. – СПб.: Издание К. Л. Риккера, 1913.

451

Каннабих Ю. В. История психиатрии. – Л.: Государственное медицинское издательство, 1928.

452

Буянин Д. Диспут о Канте закончился стрельбой в Ростове // РИА «Новости». 2013. 16 сентября.

453

Bürgy M. The Concept of Psychosis: Historical and Phenomenological Aspects. Schizophrenia Bulletin. 2008; 34(6):1200–1210.

454

Ferrero J. Lombroso's Criminal Man. – N.Y., 1919. – P. XIV.

455

Goring C. The English Convict. – L., 1913. – P. 173.

456

Cleckley, Hervey (1982). The Mask of Sanity. Revised Edition. Mosby Medical Library.

457

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. Washington, DC American Psychiatric Association; 1980.

458

Hare, R. D. (1980). A research scale for the assessment of psychopathy in criminal populations. Personality and Individual Differences, 1, 111–117.

459

Хаэр Р. Лишенные совести: Пугающий мир психопатов. – М.: Вильямс, 2014.

460

Moran P. The epidemiology of antisocial personality disorder. Soc Psychiatry Psychiatr Epidemiol. 1999; 34(5): 231–42.

461

Хаэр Р. Лишенные совести: Пугающий мир психопатов. – М.: Вильямс, 2014.

462

Antisocial Personality Disorder: Treatment, Management and Prevention. NICE Clinical Guidelines, No. 77. National Collaborating Centre for Mental Health (UK).Leicester (UK): British Psychological Society; 2010.

463

Lilienfeld SO. Doctoral Dissertation. University of Minnesota; Minneapolis: 1990. Development and preliminary validation of a slf-report of psychopathic personality.

464

Даттон К. Мудрость психопатов. – СПб.: Питер, 2014.

465

McWilliams N. Psychoanalytic Diagnosis, Understanding Personality Structure in the Clinical Process. Guilford Press; 1994.

466

Kent A. Kiehl, Peter F. Liddle, Andra M. Smith, Adrianna Mendrek, Bruce B. Forster and Robert D. Hare. Neural pathways involved in the processing of concrete and abstract words. Psychophysiology, 36 (1999).

467

Thomas ST, Sociopaths Confirm: They're Great in Bed (But They Might Treat You Like a Houseplant), Vice, July 19, 2015.

468

http://www.sociopathworld.com/

469

Dutton DL. The cold reading technique. Experientia. 1988; 44(4): 326–32.

470

Wheeler S, Book A, Costello K. Psychopathic Traits and Perceptions of Victim Vulnerability, Criminal Justice and Behavior Volume:36 Issue:6, June 2009: 635–48.

471

Cleckley HM. The Mask of Sanity. Textbook Pub; 2003.

472

Eysenck EJ, Personality and the Biosocial Model of Anti-Social and Criminal Behaviour, Biosocial Bases of Violence, Springer US, 1997: 21–37.

473

Quay, Herbert C. 1965. Psychopathic personality as pathological stimulation seeking. American Journal of Psychiatry, 122, 180–183.

474

Raine A, Fung AL, Portnoy J, Choy O, Spring VL. Low heart rate as a risk factor for child and adolescent proactive aggressive and impulsive psychopathic behavior. Aggress Behav. 2014; 40(4): 290–9.

475

Raine A, Venables PH, Mednick SA. Low resting heart rate at age 3 years predisposes to aggression at age 11 years: evidence from the Mauritius Child Health Project. J Am Acad Child Adolesc Psychiatry. 1997; 36(10): 1457–64.

476

Ortiz J, Raine A. Heart rate level and antisocial behavior in children and adolescents: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2004; 43(2): 154–62.

477

From Craig, M., Catani, M., Deeley, Q., Latham, R., Daly, E., Kanaan, R., Picchioni, M., McGuire, P., Fahy, T., & Murphy, D. (2009). Altered connections on the road to psychopathy Molecular Psychiatry, 14 (10), 946–953 DOI: 10.1038/mp.2009.40.

478

Koenigs M, Kruepke M, Newman JP. Economic decision-making in psychopathy: a comparison with ventromedial prefrontal lesion patients. Neuropsychologia. 2010; 48(7): 2198–204.

479

McWilliams N. Psychoanalytic Diagnosis, Understanding Personality Structure in the Clinical Process. Guilford Press; 1994.

480

Rothemund Y, Ziegler S, Hermann C, et al. Fear conditioning in psychopaths: event-related potentials and peripheral measures. Biol Psychol. 2012; 90(1): 50–9.

481

Birbaumer N, Veit R, Lotze M, et al. Deficient fear conditioning in psychopathy: a functional magnetic resonance imaging study. Arch Gen Psychiatry. 2005; 62(7): 799–805.

482

Hare RD. Detection threshold for electric shock in psychopaths. J Abnorm Psychol. 1968; 73(3): 268–72.

483

Blair, R. J. R. (2010). Psychopathy, frustration, and the role of reactive aggression: The role of the ventromedial prefrontal cortex. British Journal of Psychology, 101, 383–399.

484

Buckholtz JW, Treadway MT, Cowan RL, et al. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci. 2010; 13(4): 419–21.

485

Konnikova M, Stop Calling Sherlock a Sociopath! Thanks, a Psychologist, Criminal Element, Aug 8 2012, Available at: http://www.criminalelement.com/blogs/2012/08/stop-calling-sherlock-a-sociopath-psychologist-maria-konnikova. Accessed March 16, 2016.

486

Craig, M., Catani, M., Deeley, Q., Latham, R., Daly, E., Kanaan, R., Picchioni, M., McGuire, P., Fahy, T., & Murphy, D. (2009). Altered connections on the road to psychopathy Molecular Psychiatry, 14 (10).

487

Kevin M. Beavera, Matt DeLisib, Michael G. Vaughnc, J. C. Barnesa. Monoamine oxidase A genotype is associated with gang membership and weapon use.

488

Caspi A et al, Role of Genotype in the Cycle of Violence in Maltreated Children, Science, 2002 (5582/297): 851–4

489

Khalifa N, Duggan C, Stoffers J, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev. 2010; (8): CD007667.

490

Harris Grant T, et al. Psychopathy and Violent Recidivism. Law & Hum Behav. 1991; 15: 625.

491

http://www.worldsciencefestival.com/2011/09/moth_confessions_of_a_pro_social_psychopath/

492

Morton RJ, Serial Murder: Multi-Disciplinary Perspectives for Investigators, National Ctr for the Analysis of Violent Crime (NCAVC), 2008.

493

Hasler G, Hopwood CJ, Jacob GA, Brändle LS, Schulte-vels T. Patient-reported outcomes in borderline personality disorder. Dialogues Clin Neurosci. 2014; 16(2): 255–66.

494

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author: 663–6.

495

Cohen P. Child development and personality disorder. Psychiatr Clin North Am. 2008; 31(3): 477–93, vii.

496

Zanarini MC, Frankenburg FR, Reich DB, et al. Biparental failure in the childhood experiences of borderline patients. J Pers Disord. 2000; 14(3): 264–73.

497

Zanarini MC, Frankenburg FR. Pathways to the development of borderline personality disorder. J Pers Disord. 1997; 11(1): 93–104.

498

Goldman SJ, D'angelo EJ, Demaso DR. Psychopathology in the families of children and adolescents with borderline personality disorder. Am J Psychiatry. 1993; 150(12): 1832–5.

499

South SC, Turkheimer E, Oltmanns TF. Personality disorder symptoms and marital functioning. J Consult Clin Psychol. 2008; 76(5): 769–80.

500

Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatry. 2006; 188: 423–31.

501

Samuels J, Eaton WW, Bienvenu OJ, Brown CH, Costa PT, Nestadt G. Prevalence and correlates of personality disorders in a community sample. Br J Psychiatry. 2002; 180: 536–42.

502

Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry. 2001; 58(6): 590–6.

503

Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and comorbidity of DSM – IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008; 69(4): 533–45.

504

Skodol AE, Gunderson JG, Mcglashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry. 2002; 159(2): 276–83.

505

Oumaya M, Friedman S, Pham A, Abou abdallah T, Guelfi JD, Rouillon F. [Borderline personality disorder, self-mutilation and suicide: literature review]. Encephale. 2008; 34(5): 452–8.

506

Bui E, Rodgers R, Chabrol H, Birmes P, Schmitt L. Is Anakin Skywalker suffering from borderline personality disorder? Psychiatry Res. 2011; 185(1–2): 299.

507

Kreger R, Putting Darth Vader On The Couch, Psychology Today, Jun 2010.

508

Torgersen S, Lygren S, Oien PA, et al. A twin study of personality disorders. Compr Psychiatry. 2000; 41(6): 416–25.

509

Reichborn-kjennerud T, Czajkowski N, Neale MC, et al. Genetic and environmental influences on dimensional representations of DSM – IV cluster C personality disorders: a population-based multivariate twin study. Psychol Med. 2007; 37(5): 645–53.

510

Gratz AC. The Borderline Personality Disorder: Everything You Need to Know about Living with Bpd (Large Print 16pt). ReadHowYouWant.com; 2010.

511

Miller PM, Lisak D, Associations Between Childhood Abuse and Personality Disorder Symptoms in College Males J Interpers Violence June 1999, 14: 642–656.

512

Cohen P. Child development and personality disorder. Psychiatr Clin North Am. 2008; 31(3): 477–93, vii.

513

Zanarini MC, Frankenburg FR, Reich DB, et al. Biparental failure in the childhood experiences of borderline patients. J Pers Disord. 2000; 14(3): 264–73.

514

Waters E, Merrick S, Treboux D, Crowell J, Albersheim L. Attachment security in infancy and early adulthood: a twenty-year longitudinal study. Child Dev. 2000; 71(3): 684–9.

515

Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274(5292): 1527–31.

516

Rinne T, Westenberg HG, Den boer JA, Van den brink W. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry. 2000; 47(6): 548–56.

517

Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry. 2001; 50(4): 292–8.

518

Gunderson JG, Sabo AN. The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry. 1993; 150(1): 19–27.

519

Twenge JM, Gentile B, Dewall CN, Ma D, Lacefield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938–2007: A cross-temporal meta-analysis of the MMPI. Clin Psychol Rev. 2010; 30(2): 145–54.

520

Tebartz van elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry. 2003; 54(2): 163–71.

521

Rausch J, Gäbel A, Nagy K, Kleindienst N, Herpertz SC, Bertsch K. Increased testosterone levels and cortisol awakening responses in patients with borderline personality disorder: gender and trait aggressiveness matter. Psychoneuroendocrinology. 2015; 55: 116–27.

522

Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM – IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 62(6): 553–64.

523

Zanarini MC, Frankenburg FR, Hennen J, Silk KR. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003; 160(2): 274–83.

524

Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007; 27(8): 959–85.

525

Kane JM, Jeste DV, Barnes TR: Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, D.C: American Psychiatric Association; 1992. Ref Type: Report.

526

Ebert A, Kolb M, Heller J, Edel MA, Roser P, Brüne M. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma. Soc Neurosci. 2013; 8(4): 305–13.

527

Bertsch K, Gamer M, Schmidt B, et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry. 2013; 170(10): 1169–77.

528

Amad A, Thomas P, Perez-rodriguez MM. Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions. Curr Pharm Des. 2015; 21(23): 3311–6.

529

Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry. 2001; 158(1): 36–42.

530

Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry. 2009; 166(12): 1355–64.

531

Закон Российской Федерации от 2 июля 1992 г. № 3185-I (ред. от 21.11.2011 г.) «О психиатрической помощи и гарантиях прав граждан при ее оказании», ст. 27.